Lung Cancer: Non Small-Cell Patient Joeseph Robinson

February 25, 2010 by admin  
Filed under Immunotheraphy

Lung Cancer
Non Small-Cell Patient Joeseph Robinson

Joseph Robinson was 80 years old when he sought medical attention with a 23 pound weight loss, cough, marked weakness, and progressive right shoulder pain. Cell block from needle biopsy of the right upper lobe mass demonstrated adenocarcinoma, confirming the diagnosis of lung cancer which was felt to be present in both lungs. Due to age and sever disability, Mr. Robinson was not felt to be a chemotherapy candidate.

Mr. Robinson received 300 cGy in two weeks to both lung lesions and the right upper humerus which was quite sensitive to pressure clinically. His bone scan was normal.

Radiation alone in doses of this magnitude neither sterilizes sizable deposits of non small-cell lung cancer nor introduces a chance for cure in such patients. This is all the radiotherapy Mr. Robinson ever received.

Initial CT chest scan (see pre treatment below) confirmed a distinct soft tissue density mass in the right upper lobe. CT chest scan taken almost one year after diagnosis demonstrated only slight fibrotic traces in the right upper lobe. (see post treatment below)

lung-cancer_robinson_right-upper1lung-cancer_robinson_right-upper2lung-cancer_robinson_right-upper3

Initial CT chest scan (below) also confirmed a well defined left lower soft tissue density mass. CT chest scan taken almost one year after diagnosis demonstrated complete disappearance in the left lower lobe mass. (see post treatment below)

lung-cancer_robinson_left-lower1lung-cancer_robinson_left-lower2lung-cancer_robinson_left-lower3

lung-cancer_robinson_graph1

Mr. Robinson’s regulatory surface markers demonstrated the expected reciprocal fall reflecting and confirming the dramatic rise of the natural killer and B-lymphocyte populations. By newer nomenclature OKT-3=CD3, OKT-11=CD2, OKT-4=CD4, OKT-8=CD8.

lung-cancer_robinson_graph2

Mr. Robinson’s second subset analysis, using his first study as base line control, demonstrated an extreme interval rise in effector lymphocytes. Both natural killer markers, LEU-11 and LEU-7 were markedly increased well into the upper 1% of all studies at the University of Mississippi Medical Center Clinical Immunopathology Laboratory in Jackson, Mississippi. Activated T-lymphocytes, T-9, were in the upper 1%. B-lymphocytes, B4, were similarly increased.

By newer nomenclature LEU-11=CD16, and B4=CD19.

Comments are closed.